CIK 0000886744 · Large accelerated filer
GERON CORP
Sign in to watch- Ticker
- GERN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 752287752
- Phone
- 6504737700
- Business address
- 919 EAST HILLSDALE BOULEVARD, SUITE 250, FOSTER CITY, CA, 94404
- Former names
- GERON CORPORATION
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-30 | Spiegel Robert J. Director | Grant or award | +6,351 | $1.23 | $8K | 212,161 |
| 2026-06-30 | Spiegel Robert J. Director | Grant or award | +6,103 | $1.28 | $8K | 205,810 |
| 2026-05-20 | McDonald John F Director | Grant or award · Stock Option (right to buy) | +220,000 | 220,000 | ||
| 2026-05-20 | O'Farrell Elizabeth G. Director | Grant or award · Stock Option (right to buy) | +220,000 | 220,000 | ||
| 2026-05-20 | Bir Dawn Carter Director | Grant or award · Stock Option (right to buy) | +220,000 | 220,000 | ||
| 2026-05-20 | Molineaux Susan Director | Grant or award · Stock Option (right to buy) | +220,000 | 220,000 | ||
| 2026-05-20 | Spiegel Robert J. Director | Grant or award · Stock Option (right to buy) | +220,000 | 220,000 | ||
| 2026-04-13 | Williams Timothy EVP and Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +2,500,000 | 2,500,000 | ||
| 2026-03-31 | Spiegel Robert J. Director | Grant or award | +5,243 | $1.49 | $8K | 199,707 |
| 2026-03-25 | Chinoporos Constantine Director | Grant or award · Stock Option (Right to Buy) | +270,000 | 270,000 | ||
| 2026-03-25 | Andrews Patricia S Director | Grant or award · Stock Option (Right to Buy) | +270,000 | 270,000 | ||
| 2026-02-18 | ROBERTSON MICHELLE EVP, CHIEF FINANCIAL OFFICER | Option exercise | +27,500 | 27,500 | ||
| 2026-02-18 | ROBERTSON MICHELLE EVP, CHIEF FINANCIAL OFFICER | Sale | −9,855 | $1.94 | $19K | 17,645 |
| 2026-02-18 | ROBERTSON MICHELLE EVP, CHIEF FINANCIAL OFFICER | Option exercise · Restricted Stock Units | −27,500 | 82,500 | ||
| 2026-02-17 | Eid Joseph EVP, R&D; Chief Medical Office | Grant or award · Stock Option (Right to Buy) | +2,220,000 | 2,220,000 | ||
| 2026-02-17 | ROBERTSON MICHELLE EVP, CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (Right to Buy) | +1,660,000 | 1,660,000 | ||
| 2025-12-31 | Spiegel Robert J. Director | Grant or award | +5,918 | $1.32 | $8K | 194,464 |
| 2025-10-20 | ElNawawi Ahmed EVP, Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +3,000,000 | 3,000,000 | ||
| 2025-09-30 | Spiegel Robert J. Director | Grant or award | +5,702 | $1.37 | $8K | 188,546 |
| 2025-08-07 | Semerjian Harout President and CEO | Grant or award · Stock Option (right to buy) | +7,000,000 | 7,000,000 |
Page 1 of 7 · 138 trades